Search research articles

Search research articles

Related Experiment Videos

Enfuvirtide (T-20): potentials and challenges.

Karlissa Foy¹, Salomé N Juethner

¹Community Research Initiative of New England, Boston, USA.

The Journal of the Association of Nurses in AIDS Care : JANAC

|November 13, 2004

Summary

This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Enfuvirtide nursing guidelines: a report from the Association of Nurses in AIDS Care Expert Panel on Enfuvirtide.

The Journal of the Association of Nurses in AIDS Care : JANAC·2006

Same author

Tolerance of efavirenz-induced central nervous system side effects in HIV-infected individuals with a history of substance abuse.

HIV clinical trials·2003

Same author

Nonnucleoside reverse transcriptase inhibitor resistance among antiretroviral-naive HIV-positive pregnant women.

Journal of acquired immune deficiency syndromes (1999)·2003

See all related articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Enfuvirtide (T-20) is an effective HIV fusion inhibitor, well-tolerated by patients who self-inject. Most patients find self-injection manageable and it doesn't impede daily life.

Area of Science:

Virology
Immunology
Pharmacology

Background:

Enfuvirtide (T-20) is a peptide fusion inhibitor crucial for managing HIV infection.
As an injectable medication, patient self-administration (reconstitution and injection) is integral to its therapeutic regimen.

Purpose of the Study:

To present comprehensive results from Phase III clinical trials of enfuvirtide.
To evaluate the efficacy, tolerability, pharmacokinetics, resistance patterns, and adverse events associated with enfuvirtide therapy.
To assess patient perspectives on self-injection and address clinical prescribing considerations.

Main Methods:

Analysis of data from Phase III clinical trials involving enfuvirtide.
Review of pharmacokinetic and resistance data.

Related Experiment Videos

Summarization of patient-reported outcomes regarding self-injection.

Examination of adverse events, particularly injection site reactions (ISRs).

Main Results:

Enfuvirtide demonstrated favorable efficacy and tolerability in Phase III trials.
No significant pharmacokinetic interactions have been reported.
The majority of patients found self-injection easy to manage and compatible with daily activities.
Injection site reactions (ISRs) were common but manageable with appropriate nursing interventions.

Conclusions:

Enfuvirtide is a well-tolerated and effective treatment option for HIV infection, with patient self-injection being generally well-received.
Understanding and managing ISRs is key to optimizing enfuvirtide therapy.
Further research and clinician support are needed to facilitate broader prescribing of enfuvirtide.